Currently, a plethora of clinical trials at various phases are ongoing to assess the safety and clinical efficacy of antibodies directed at cell surface markers expressed on MDS and AML stem cells, with an increasing trend of using bispecific, immune cell engaging properties ( www.clinicaltrials.gov ).
← all excerpts
Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia.
1
—
—